C07K 2317/71
Decreased effector function due to an fc-modification
Official title: Decreased effector function due to an Fc-modification
C07K2317/71 (Decreased effector function due to an fc-modification) appears on 1,006 US grants and 2,332 published applications in this corpus.
Search patents in C07K- Granted patents
- 1,006
- Published applications
- 2,332
- Assignees
- 633
- Inventors
- 4,144
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2001 | 1 | 1 |
| 2002 | 1 | 1 |
| 2003 | 1 | 3 |
| 2004 | 2 | 5 |
| 2005 | 1 | 8 |
| 2006 | 2 | 9 |
| 2007 | 2 | 26 |
| 2008 | 6 | 24 |
| 2009 | 3 | 28 |
| 2010 | 6 | 25 |
| 2011 | 14 | 20 |
| 2012 | 13 | 35 |
| 2013 | 20 | 49 |
| 2014 | 30 | 63 |
| 2015 | 33 | 78 |
| 2016 | 39 | 96 |
| 2017 | 48 | 109 |
| 2018 | 58 | 125 |
| 2019 | 75 | 144 |
| 2020 | 76 | 159 |
| 2021 | 100 | 188 |
| 2022 | 89 | 208 |
| 2023 | 87 | 203 |
| 2024 | 103 | 275 |
| 2025 | 129 | 265 |
| 2026 | 67 | 185 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods of treating lupus nephritis6 Oct 2026US 12,752,005 B2Genentech, Inc.
- Methods and antibody compositions for tumor treatment29 Sep 2026US 12,747,300 B2Regeneron Pharmaceuticals, Inc.
- CLDN18.2/CD3 bispecific antibodies for the therapy of CLDN18.2-expressing solid tumors22 Sep 2026US 12,742,008 B2Shandong Boan Biotechnology Co., Ltd.
- Monoclonal antibodies against CLDN18.2 and Fc-engineered versions thereof15 Sep 2026US 12,735,479 B2Shijiazhuang Yiling Pharmaceutical Co., Ltd.
- Anti-hemojuvelin (HJV) antibodies for treating myelofibrosis25 Aug 2026US 12,715,916 B2AbbVie Deutschland GmbH & Co. KG
- Anti-ox40 antibody and uses thereof8 Oct 2026US 2026/0308267 A1Hutchison Medipharma Limited
- Risankizumab compositions1 Oct 2026US 2026/0297178 A1AbbVie Inc.
- Humanised antibodies and uses thereof24 Sep 2026US 2026/0284244 A1Telix Pharmaceuticals (Innovations) Pty Ltd.
- Risankizumab compositions24 Sep 2026US 2026/0285967 A1AbbVie Inc.
- Monospecific anti-frizzled antibodies and methods of use24 Sep 2026US 2026/0285987 A1Surrozen Operating, Inc.
Most cited
By later US patents
- Polypeptide variants with altered effector function1,378US 6,737,056 B1Genentech, Inc. · 2004
- Polypeptide variants521US 6,528,624 B1Genentech, Inc. · 2003
- Optimized Fc variants463US 7,317,091 B2Xencor, Inc. · 2008
- Anti-PD-L1 antibodies, compositions and articles of manufacture459US 8,217,149 B2Genentech, Inc. · 2012
- Polypeptide variants with altered effector function373US 7,332,581 B2Genentech, Inc. · 2008